Compound · clinical trials

Daratumumab clinical trials

Also listed in trial records as Darzalez, JNJ-54767414, CT-P44, HuMax-CD38

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 103 trials in our USA, China, France, Spain, Italy, Australia, Germany, UK, Japan, Netherlands, Israel, Canada, Poland, Belgium, South Korea, Czechia, Brazil, Denmark, Norway, Turkey, Taiwan, Sweden, Switzerland, Austria, Portugal, Ireland, India, Mexico, Singapore and Egypt registers that name Daratumumab as an intervention. Synced 9 Nov 2026

103Current trials

51Recruiting now

56Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Daratumumab is named as an intervention in 103 current clinical trials in our USA, China, France, Spain, Italy, Australia, Germany, UK, Japan, Netherlands, Israel, Canada, Poland, Belgium, South Korea, Czechia, Brazil, Denmark, Norway, Turkey, Taiwan, Sweden, Switzerland, Austria, Portugal, Ireland, India, Mexico, Singapore and Egypt registers. 51 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Janssen Research & Development, LLC (13). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 8 authorised or ongoing trials.

Daratumumab also has an approved-drug profile on this site (FDA label data): Darzalex (Daratumumab) →

Where Daratumumab is approved

All regulators →

Of the three regulators tracked here, the first to approve Daratumumab was the US, on 16 Nov 2015. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

16 Nov 2015

Darzalex

BLA761036 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

20 May 2016

Darzalex

EMA product page

First centralised authorisation

CACanada (Health Canada)

29 Jun 2016

Darzalex

Notice of Compliance 18215

First new-drug NOC

2 EU orphan designations, most recently for treatment of AL amyloidosis (25 May 2018, withdrawn)

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Daratumumab

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$10.5m

2,170 prescriptions in 2025 · Darzalex IV, Darzalex

-29% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Daratumumab works

All drug targets →

Lymphocyte differentiation antigen CD38 inhibitor Inhibitor
Target: CD38 CD38 molecule
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on CD38

Isatuximab Felzartamab Mezagitamab

Diseases it has been tested for in clinical trials, by furthest phase

AL amyloidosisPhase 3
Acute leukemiaPhase 3
Autoimmune encephalitisPhase 3
LeukemiaPhase 3
Smoldering plasma cell myelomaPhase 3
T-lymphoblastic lymphomaPhase 2/3
Neuromyelitis opticaPhase 2/3
Alzheimer diseasePhase 2
B-cell chronic lymphocytic leukemiaPhase 2
Evans syndromePhase 2

70 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1743007, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7395, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Daratumumab

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 13 technology appraisals of Daratumumab. 12 are current, and 7 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable NICE TA1195	Optimised	30 Sep 2026	Current
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable NICE TA1170	Optimised	24 Jun 2026	Current
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis NICE TA959	Optimised	27 Mar 2024	Current
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable NICE TA917	Recommended	25 Oct 2023	Current
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma NICE TA897	Optimised	6 Jun 2023	Current
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma NICE TA783	Optimised	13 Apr 2022	Current
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) NICE TA771	Terminated (no company submission)	9 Feb 2022	Current
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable NICE TA763	Recommended	2 Feb 2022	Current

See all 12 appraisals →

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Daratumumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 2 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Darzalex
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Daratumumab

ATC code: L01XC24
ChEMBL: CHEMBL1743007
DrugBank: DB09331
CAS number: 945721-28-8
FDA UNII: 4Z63YK6E0E
Wikidata: Q5222113
Wikipedia: Daratumumab

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting5150%
Not yet open77%
Active, closed4544%

Trials by phase

Phase 24039%
Phase 33534%
Phase 1/21111%
Phase 199%
Phase 433%
Phase 2/322%
Not applicable22%
Early Phase 111%

Clinical trials of Daratumumab

103 trials

Study	Phase	Status	Lead sponsor	Registers
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702 · ClinicalTrials.gov ↗ · Newly Diagnosed, High Risk, MRD	Phase 4	Recruiting	The First Affiliated Hospital of Soochow University	China
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia NCT07788456 · ClinicalTrials.gov ↗ · ITP - Immune Thrombocytopenia	Phase 4	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma NCT03937635 · ClinicalTrials.gov ↗ · Smoldering Plasma Cell Myeloma	Phase 3	Recruiting	ECOG-ACRIN Cancer Research Group	Egypt
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments NCT05020236 · Multiple Myeloma	Phase 3	Recruiting	Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma NCT05552222 · Multiple Myeloma	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant NCT05623020 · Multiple Myeloma	Phase 3	Recruiting	Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma NCT06182774 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Canadian Cancer Trials Group	Canada
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) NCT06187441 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)	Phase 3	Recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	GlaxoSmithKline	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis NCT06867991 · ClinicalTrials.gov ↗ · Anti-N-Methyl-D-Aspartate Receptor Encephalitis	Phase 3	Recruiting	The First People's Hospital of Changzhou	China
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients NCT06918002 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed	Phase 3	Recruiting	Intergroupe Francophone du Myelome	France, Belgium
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant NCT06932562 · Multiple Myeloma	Phase 3	Recruiting	European Myeloma Network B.V	Ireland, Germany, Spain, Italy, Netherlands, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Australia
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07222761 · Relapsed and/or Refractory Multiple Myeloma (RRMM)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, Turkey, Brazil, South Korea, Taiwan, Australia
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) NCT07391657 · Relapsed Refractory Multiple Myeloma	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Poland, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) NCT07393282 · High Risk Smoldering Multiple Myeloma (HR-SMM)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, France, Poland, Japan, South Korea
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma NCT07452198 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Genrix (Shanghai) Biopharmaceutical Co., Ltd	China
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma NCT07555938 · Multiple Myeloma	Phase 3	Recruiting	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Czechia, Canada, Brazil, Japan, South Korea, Australia, Israel
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 3	Recruiting	Innovent Biologics (Suzhou) Co. Ltd	China
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned NCT07665450 · Multiple Myeloma	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, Germany, France, Spain, Italy, Netherlands, Poland, Czechia, Portugal, Turkey, South Korea, Australia, Israel
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT NCT07764978 · Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	AstraZeneca	UK, USA, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07095452 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2/3	Recruiting	AbbVie	USA, France, Spain, Japan
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248 · ClinicalTrials.gov ↗ · Plasmablastic Lymphoma	Phase 2	Recruiting	Fondazione Italiana Linfomi - ETS	Italy
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 NCT05695508 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Recruiting	University of Heidelberg Medical Center	Germany
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients NCT06505369 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Recruiting	North Estonia Medical Centre	Denmark, Norway
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) NCT06838962 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma NCT07018050 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 2	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" NCT07021677 · ClinicalTrials.gov ↗ · T Acute Lymphoblastic Leukemia	Phase 2	Recruiting	Tata Memorial Centre	India
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) NCT07045909 · ClinicalTrials.gov ↗ · De Novo Multiple Myeloma, Anitocabtagene Autoleucel	Phase 2	Recruiting	PETHEMA Foundation	Spain
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) NCT07063199 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. NCT07107529 · Multiple Myeloma (MM)	Phase 2	Recruiting	European Myeloma Network B.V	Spain, Italy, Netherlands, Norway
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) NCT07297563 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis NCT07335887 · ClinicalTrials.gov ↗ · AL Amyloidosis (AL), t(11;14) Positive	Phase 2	Recruiting	Peking University People's Hospital	China
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) NCT07362238 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683 · ClinicalTrials.gov ↗ · Multiple Myeloma, AL Amyloidosis	Phase 2	Recruiting	Shanghai Zhongshan Hospital	China
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma NCT07891923 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma (NDMM)	Phase 2	Recruiting	Tata Memorial Centre	India
Selinexor and Backbone Treatments of Multiple Myeloma Patients NCT02343042 · Multiple Myeloma	Phase 1/2	Recruiting	Karyopharm Therapeutics Inc	USA, Canada
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma	Phase 1/2	Recruiting	CellCentric Ltd	UK, USA, France, Spain, Sweden
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605 · Relapsed/Refractory Multiple Myeloma	Phase 1/2	Recruiting	BeOne Medicines	UK, USA, China, Germany, France, Spain, Italy, Canada, Brazil, South Korea, Singapore, Australia
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers NCT06119685 · NHL, Multiple Myeloma, Blood Cancer	Phase 1/2	Recruiting	Indapta Therapeutics, INC	USA
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations NCT06892522 · Multiple Myeloma	Phase 1/2	Recruiting	AbbVie	UK, USA, Norway, Japan, Australia, Israel
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) NCT06953960 · Multiple Myeloma	Phase 1/2	Recruiting	AbbVie	UK, USA, Germany, France, Italy, Belgium, Sweden, Poland, Portugal, Japan, Australia, Israel
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia NCT07287228 · ClinicalTrials.gov ↗ · Aplastic Anemia, Refractory, Relapse	Phase 1/2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596 · Relapsed or Refractory Multiple Myeloma	Phase 1/2	Recruiting	AstraZeneca	USA, Australia
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04910568 · Multiple Myeloma	Phase 1	Recruiting	Genentech, Inc	UK, USA, France, Spain, Italy, Denmark, Poland, Czechia, Canada, Japan, South Korea, Australia, Israel
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments NCT05137054 · Multiple Myeloma	Phase 1	Recruiting	Regeneron Pharmaceuticals	USA, France, Spain, Israel
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma NCT06768489 · Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis	Phase 1	Recruiting	Janssen Research & Development, LLC	USA, Spain, Netherlands, Australia, Israel
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979 · ClinicalTrials.gov ↗ · Amyloidosis; Systemic, AL Amyloidosis	Not applicable	Recruiting	Jin Lu, MD	China
Risk Stratification and MRD-driven Maintenance for MM After ASCT NCT06697483 · ClinicalTrials.gov ↗ · Multiple Myeloma	Not applicable	Recruiting	Peking University People's Hospital	China
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma NCT07728188 · Relapsed or Refractory Multiple Myeloma	Phase 3	Not yet open	AbbVie	UK, USA, Germany, France, Spain, Italy, Netherlands, Norway, Portugal, Canada, Taiwan, Australia, Israel
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma NCT07910903 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)	Phase 3	Not yet open	Keymed Biosciences Co.Ltd	China
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) NCT06931704 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Nantes University Hospital	France
A Open-Label Phase in Participants With Multiple Myeloma NCT07764861 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd	China
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma NCT07830485 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Institute of Hematology & Blood Diseases Hospital, China	China
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. NCT07110662 · ClinicalTrials.gov ↗ · Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)	Phase 1/2	Not yet open	Hospices Civils de Lyon	France
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study NCT07026604 · ClinicalTrials.gov ↗ · Cavernous Malformation, Cerebral	Early Phase 1	Not yet open	Beijing Tiantan Hospital	China
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA NCT03829371 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 4	Active, closed	University of Turin, Italy	Italy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma NCT03710603 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Stichting European Myeloma Network	France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Turkey, Australia
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years NCT03742297 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 3	Active, closed	PETHEMA Foundation	Spain
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma NCT04181827 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Japan, South Korea, Australia, Israel
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT04246047 · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	USA, China, Spain, Italy, Netherlands, Belgium, Poland, Japan, South Korea, Australia, Israel
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT04975997 · Multiple Myeloma	Phase 3	Active, closed	Celgene	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma NCT05083169 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma NCT05257083 · Multiple Myeloma	Phase 3	Active, closed	Stichting European Myeloma Network	Germany, France, Spain, Netherlands, Belgium, Sweden, Switzerland, Czechia, Norway, Canada, Japan, Australia, Israel
A Study of Daratumumab NCT05438043 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Turkey, Brazil, South Korea
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment NCT05455320 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma NCT06413498 · Multiple Myeloma	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Canada, Mexico, Japan, Australia
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) NCT06464991 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Nanjing IASO Biotechnology Co., Ltd	China, Japan
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT06868654 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	China
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT06868667 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	GlaxoSmithKline	Japan
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma NCT06952478 · ClinicalTrials.gov ↗ · Refractory or Relapsed Multiple Myeloma	Phase 3	Active, closed	Celltrion	Taiwan
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders NCT05403138 · ClinicalTrials.gov ↗ · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder	Phase 2/3	Active, closed	Tianjin Medical University General Hospital	China
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma NCT03236428 · ClinicalTrials.gov ↗ · Monoclonal Gammopathy, Smoldering Multiple Myeloma	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma NCT03314181 · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA, Germany, France, Denmark, Canada, Japan, Australia, Israel
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222 · ClinicalTrials.gov ↗ · Refractory Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients NCT03606577 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Nantes University Hospital	France
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction NCT03734198 · ClinicalTrials.gov ↗ · Relapsed or Refractory Chronic Lymphocytic Leukemia	Phase 2	Active, closed	French Innovative Leukemia Organisation	France
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara NCT03896737 · Multiple Myeloma	Phase 2	Active, closed	European Myeloma Network B.V	Italy, Czechia
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients NCT04124497 · ClinicalTrials.gov ↗ · Multiple Myeloma, Deletion 17P Syndrome	Phase 2	Active, closed	Fondazione EMN Italy Onlus	Italy
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma NCT04133636 · Multiple Myeloma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA, Germany, France, Spain, Netherlands, Belgium, Israel
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease NCT04166565 · ClinicalTrials.gov ↗ · Multiple Myeloma, Extramedullary Plasmacytoma	Phase 2	Active, closed	Stichting European Myeloma Network	Italy, Turkey
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM NCT04176718 · Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse	Phase 2	Active, closed	Andrew Yee, MD	Israel
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse NCT04656951 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	University of Cologne	Germany
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma NCT04782687 · Multiple Myeloma, Myeloma Multiple, Kahler Disease	Phase 2	Active, closed	US Oncology Research	USA
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis NCT05250973 · Amyloidosis	Phase 2	Active, closed	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Canada
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. NCT05527340 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma NCT05572229 · Multiple Myeloma	Phase 2	Active, closed	University Hospital, Lille	France
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma NCT05849610 · ClinicalTrials.gov ↗ · High-Risk de Novo Multiple Myeloma	Phase 2	Active, closed	PETHEMA Foundation	Spain
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program NCT06253637 · ClinicalTrials.gov ↗ · T-Lymphocytic Leukemia, Acute	Phase 2	Active, closed	Gruppo Italiano Malattie EMatologiche dell'Adulto	Italy
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma NCT06353022 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Nantes University Hospital	France
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma NCT06577025 · Multiple Myeloma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA, Germany, Spain, Brazil, Australia
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) NCT06629818 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial NCT07902609 · ClinicalTrials.gov ↗ · Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)	Phase 2	Active, closed	First Affiliated Hospital, Sun Yat-Sen University	China
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma NCT02773030 · Multiple Myeloma	Phase 1/2	Active, closed	Celgene	UK, USA, Germany, France, Spain, Italy, Netherlands, Canada, Japan, Australia, Israel
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) NCT03989414 · Multiple Myeloma	Phase 1/2	Active, closed	Celgene	USA, Germany, France, Spain, Italy, Denmark, Czechia, Canada
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma NCT04108195 · Multiple Myeloma	Phase 1	Active, closed	Janssen Research & Development, LLC	USA, Germany, Spain, Netherlands, Canada
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. NCT04667663 · Multiple Myeloma	Phase 1	Active, closed	Cancer Trials Ireland	Ireland
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma NCT04722146 · Multiple Myeloma	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA, France, Belgium, Australia
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma NCT05050097 · Multiple Myeloma	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA, France, Netherlands, Belgium, Australia
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma NCT05259839 · Relapsed/Refractory Multiple Myeloma	Phase 1	Active, closed	AbbVie	USA, Germany, Spain, Italy, Poland, Japan, Australia
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets NCT05308654 · Relapsed/Refractory Multiple Myeloma	Phase 1	Active, closed	AbbVie	UK, USA, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Daratumumab in the EU trials register (CTIS)

8 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Daratumumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5). 2025-524014-29-00 · Neoplasms	Phase 3	Authorised	AstraZeneca AB	Poland, Italy, Denmark + 4 more
A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma 2025-523252-31-00 · Neoplasms	Phase 3	Ongoing	Regeneron Pharmaceuticals Inc	Italy, Spain, Poland + 4 more
Phase 3 Randomized Study of Teclistamab and Talquetamab (Tec-Tal) Versus Daratumumab and Lenalidomide (DR) in Minimal Residual Disease (MRD) Positive Patients With Newly Diagnosed Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation (TiTan) 2025-525097-11-00 · Hemic and Lymphatic Diseases	Phase 3	Authorised	Polish Myeloma Consortium	Poland
Prospective, multicentre, two-arms, I/II phase study to Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) 2024-513917-11-01 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 1	Authorised	Uniwersytet Medyczny W Lublinie	Poland
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4) 2025-523285-25-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	AstraZeneca AB	Norway, Poland, Spain + 3 more
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma 2025-524876-43-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Universitair Medisch Centrum Groningen	Netherlands
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma 2024-519504-27-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Regeneron Pharmaceuticals Inc	Greece, Spain, Poland + 7 more
EFfIcacy and Tolerability of FIXed duration teclistamab and talquetamab FOR FRAIL patients with newly diagnosed multiple myeloma (2 cohort study) - the EMN 37 FITFIX FOR FRAIL trial 2024-520433-76-00 · CTIS ↗ · Neoplasms	Phase 2	Ongoing	European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale	Norway, Italy, Spain + 1 more

Daratumumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

2 single-substance products containing Daratumumab on the HPRA medicines list.

DARZALEX 1800 mg solution for injectionJanssen-Cilag International NV · EU/1/16/1101/004
DARZALEX 20 mg/mL concentrate for solution for infusionJanssen-Cilag International NV · EU/1/16/1101/001-003

All 2 Irish products →

Supply shortages

No entry for Daratumumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Daratumumab

64 conditions

Multiple Myeloma60 Relapsed or Refractory Multiple Myeloma4 Immune Thrombocytopenia4 Treatment4Newly Diagnosed Multiple Myeloma3Relapsed/Refractory Multiple Myeloma3Smoldering Multiple Myeloma2Relapse2AL Amyloidosis2Multiple Myeloma (MM)2Refractory Multiple Myeloma2Cancer1

All 64 conditions

Condition (as registered)	Trials
Multiple Myeloma	60
Relapsed or Refractory Multiple Myeloma	4
Immune Thrombocytopenia	4
Treatment	4
Newly Diagnosed Multiple Myeloma	3
Relapsed/Refractory Multiple Myeloma	3
Smoldering Multiple Myeloma	2
Relapse	2
AL Amyloidosis	2
Multiple Myeloma (MM)	2
Refractory Multiple Myeloma	2
Cancer	1
Relapsed Refractory Multiple Myeloma	1
Relapsed or Refractory Multiple Myeloma (RRMM)	1
Amyloidosis	1
Haematological Malignancy	1
Acute Myeloid Leukemia	1
Non Hodgkin Lymphoma	1
Relapsed and/or Refractory Multiple Myeloma (RRMM)	1
High Risk Smoldering Multiple Myeloma (HR-SMM)	1
Myeloma Multiple	1
Kahler Disease	1
Myeloma, Plasma Cell	1
NHL	1
Blood Cancer	1
Refractory Non-Hodgkin Lymphoma	1
Immunoglobulin Light-chain Amyloidosis	1
T Acute Lymphoblastic Leukemia	1
Newly Diagnosed Multiple Myeloma (NDMM)	1
Cavernous Malformation, Cerebral	1
Aplastic Anemia	1
Refractory	1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis	1
AL Amyloidosis (AL)	1
t(11;14) Positive	1
Amyloidosis; Systemic	1
Neuromyelitis Optica	1
Neuromyelitis Optica Spectrum Disorder	1
NMO Spectrum Disorder	1
Light Chain (AL) Amyloidosis	1
Newly Diagnosed	1
High Risk	1
MRD	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
Antibody-mediated Rejection	1
Antibody-Mediated Rejection (AMR)	1
ITP - Immune Thrombocytopenia	1
Toxic Epidermal Necrolysis	1
Immunotherapy	1
Cutaneous Adverse Drug Reactions (CADR)	1
Relapsed or Refractory Chronic Lymphocytic Leukemia	1
Multiple Myeloma, Newly Diagnosed	1
High-Risk de Novo Multiple Myeloma	1
De Novo Multiple Myeloma	1
Anitocabtagene Autoleucel	1
Deletion 17P Syndrome	1
Plasmablastic Lymphoma	1
Extramedullary Plasmacytoma	1
T-Lymphocytic Leukemia, Acute	1
Refractory or Relapsed Multiple Myeloma	1
Monoclonal Gammopathy	1
Multiple Myeloma in Relapse	1
Smoldering Plasma Cell Myeloma	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	42	22
Clinical trials in China	40	25
Clinical trials in France	40	18
Clinical trials in Spain	40	19
Clinical trials in Italy	34	16
Clinical trials in Australia	32	18
Clinical trials in Germany	31	14
Clinical trials in UK	29	17
Clinical trials in Japan	26	14
Clinical trials in Netherlands	24	10
Clinical trials in Israel	24	12
Clinical trials in Canada	23	13
Clinical trials in Poland	22	13
Clinical trials in Belgium	20	8
Clinical trials in South Korea	20	14
Clinical trials in Czechia	18	10
Clinical trials in Brazil	16	11
Clinical trials in Denmark	15	8
Clinical trials in Norway	14	10
Clinical trials in Turkey	14	8
Clinical trials in Taiwan	13	8
Clinical trials in Sweden	12	8
Clinical trials in Switzerland	9	5
Clinical trials in Austria	8	6
Clinical trials in Portugal	8	6
Clinical trials in Ireland	5	3
Clinical trials in India	4	3
Clinical trials in Mexico	4	2
Clinical trials in Singapore	2	2
Clinical trials in Egypt	1	1
EU register (CTIS)	8	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Daratumumab trials

How many clinical trials are testing Daratumumab?

103 current trials in our USA, China, France, Spain, Italy, Australia, Germany, UK, Japan, Netherlands, Israel, Canada, Poland, Belgium, South Korea, Czechia, Brazil, Denmark, Norway, Turkey, Taiwan, Sweden, Switzerland, Austria, Portugal, Ireland, India, Mexico, Singapore and Egypt registers name Daratumumab (also registered as JNJ-54767414) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Daratumumab trials recruiting patients?

Yes. 51 of the 103 trials are recruiting: 22 with sites in USA, 25 with sites in China, 18 with sites in France, 19 with sites in Spain, 16 with sites in Italy, 18 with sites in Australia, 14 with sites in Germany, 17 with sites in UK, 14 with sites in Japan, 10 with sites in Netherlands, 12 with sites in Israel, 13 with sites in Canada, 13 with sites in Poland, 8 with sites in Belgium, 14 with sites in South Korea, 10 with sites in Czechia, 11 with sites in Brazil, 8 with sites in Denmark, 10 with sites in Norway, 8 with sites in Turkey, 8 with sites in Taiwan, 8 with sites in Sweden, 5 with sites in Switzerland, 6 with sites in Austria, 6 with sites in Portugal, 3 with sites in Ireland, 3 with sites in India, 2 with sites in Mexico, 2 with sites in Singapore and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Daratumumab clinical trials?

Janssen Research & Development, LLC (13), AbbVie (7), Institute of Hematology & Blood Diseases Hospital, China (7) and PETHEMA Foundation (5), among 56 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Daratumumab clinical trials in Ireland?

Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Daratumumab licensed in Ireland?

Yes. The HPRA medicines list includes 2 single-substance products containing Daratumumab, for example DARZALEX 1800 mg solution for injection (Janssen-Cilag International NV). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Daratumumab shortage?

Not in the lists we track: Daratumumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Daratumumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Daratumumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Daratumumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Daratumumab clinical trials

Where Daratumumab is approved

What health systems spend on Daratumumab

How Daratumumab works

NICE appraisals of Daratumumab

Patient leaflets for Daratumumab

Reference identifiers for Daratumumab

Trials by status

Trials by phase

Clinical trials of Daratumumab

Daratumumab in the EU trials register (CTIS)

Daratumumab across our data

Licensed in Ireland (HPRA)

Supply shortages

Conditions studied with Daratumumab

Sponsors

By country register

Related compounds

In the same trials as Daratumumab

Other compounds in Multiple Myeloma trials

Questions about Daratumumab trials

How this page is built